Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Showing posts with label Neurogenin2. Show all posts
Showing posts with label Neurogenin2. Show all posts

Monday, February 10, 2025

Glial Cell Reprogramming in Ischemic Stroke: A Review of Recent Advancements and Translational Challenges

 Is this far enough along for your competent? doctor TO ENSURE HUMAN TESTING GETS DONE? You mean your doctor has no idea on contacting leadership to get necessary research accomplished? And s/he HASN'T BEEN FIRED YET?

Glial Cell Reprogramming in Ischemic Stroke: A Review of Recent Advancements and Translational Challenges

Ischemic stroke, the second leading cause of death worldwide and the leading cause of long-term disabilities, presents a significant global health challenge, particularly in aging populations where the risk and severity of cerebrovascular events are significantly increased. The aftermath of stroke involves neuronal loss in the infarct core and reactive astrocyte proliferation, disrupting the neurovascular unit, especially in aged brains. Restoring the balance between neurons and non-neuronal cells within the perilesional area is crucial for post-stroke recovery. The aged post-stroke brain mounts a fulminant proliferative astroglial response, leading to gliotic scarring that prevents neural regeneration. While countless therapeutic techniques have been attempted for decades with limited success, alternative strategies aim to transform inhibitory gliotic tissue into an environment conducive to neuronal regeneration and axonal growth through genetic conversion of astrocytes into neurons. This concept gained momentum following discoveries that in vivo direct lineage reprogramming in the adult mammalian brain is a feasible strategy for reprogramming non-neuronal cells into neurons, circumventing the need for cell transplantation. Recent advancements in glial cell reprogramming, including transcription factor-based methods with factors like NeuroD1, Ascl1, and Neurogenin2, as well as small molecule-induced reprogramming and chemical induction, show promise in converting glial cells into functional neurons. These approaches leverage the brain’s intrinsic plasticity for neuronal replacement and circuit restoration. However, applying these genetic conversion therapies in the aged, post-stroke brain faces significant challenges, such as the hostile inflammatory environment and compromised regenerative capacity. There is a critical need for safe and efficient delivery methods, including viral and non-viral vectors, to ensure targeted and sustained expression of reprogramming factors. Moreover, addressing the translational gap between preclinical successes and clinical applications is essential, emphasizing the necessity for robust stroke models that replicate human pathophysiology. Ethical considerations and biosafety concerns are critically evaluated, particularly regarding the long-term effects and potential risks of genetic reprogramming. By integrating recent research findings, this comprehensive review provides an in-depth understanding of the current landscape and future prospects of genetic conversion therapy for ischemic stroke rehabilitation, highlighting the potential to enhance personalized stroke management and regenerative strategies through innovative approaches.

Saturday, July 27, 2024

Glial Cells Reprogrammed to Neurons for Brain Repair

 Ask your competent? doctor if anything here will get you recovered from your stroke. If your doctor doesn't even know about this research; YOU DON'T HAVE A FUNCTIONING STROKE DOCTOR!

Glial Cells Reprogrammed to Neurons for Brain Repair

Summary: Researchers have discovered how glial cells can be reprogrammed into neurons through epigenetic modifications, offering hope for treating neurological disorders. This reprogramming involves complex molecular mechanisms, including the transcription factor Neurogenin2 and the newly identified protein YingYang1, which opens chromatin for reprogramming.

The study reveals how coordinated epigenome changes drive this process, potentially leading to new therapies for brain injury and neurodegenerative diseases.

Key Facts:

  1. Neuronal Reprogramming: Glial cells can be transformed into neurons via epigenetic modifications.
  2. Key Players: Neurogenin2 and YingYang1 are crucial for the reprogramming process.
  3. Therapeutic Potential: This discovery could lead to new treatments for brain disorders and injuries.

Source: LUM

Researchers at LMU and Helmholtz Munich have shown how glial cells are reprogrammed into neurons via epigenetic modifications.

Neurological disorders, such as trauma, stroke, epilepsy, and various neurodegenerative diseases, often lead to the permanent loss of neurons, causing significant impairments in brain function.

Current treatment options are limited, primarily due to the challenge of replacing lost neurons. Direct neuronal reprogramming, a complex procedure that involves changing the function of one type of cell into another, offers a promising strategy.

This shows glial cells.
For the first time, the teams have now shown how coordinated the epigenome rewiring is, elicited by a single transcription factor. Credit: Neuroscience News

In cell culture and in living organisms, glial cells – the non-neuronal cells in the central nervous system – have been successfully transformed into functional neurons. However, the processes involved in this reprogramming are complex and require further understanding.

This complexity presents a challenge, but also a motivation, for researchers in the field of neuroscience and regenerative medicine.

Modifications in the epigenome

Two teams, one led by Magdalena Götz, Chair of Physiological Genomics at LMU, Head of the Stem Cell Center Department at Helmholtz Munich, and researcher in the SyNergy Cluster of Excellence, and the other led by Boyan Bonev at the Helmholtz Pioneer Campus, explored the molecular mechanisms at play when glial cells are converted to neurons by a single transcription factor. Specifically, the researchers focused on small chemical modifications in the epigenome.

The epigenome helps control which genes are active in different cells at different times. For the first time, the teams have now shown how coordinated the epigenome rewiring is, elicited by a single transcription factor.

Using novel methods in epigenome profiling, the researchers identified that a posttranslational modification of the reprogramming neurogenic transcription factor Neurogenin2 profoundly impacts the epigenetic rewiring and neuronal reprogramming.

However, the transcription factor alone is not enough to reprogram the glial cells. In an important discovery, the researchers identified a novel protein, the transcriptional regulator YingYang1, as a key player in this process. YingYang1 is necessary to open up the chromatin for reprogramming, to which end it interacts with the transcription factor.

“The protein Ying Yang 1 is crucial for achieving the conversion from astrocytes to neurons,” explains Götz.

“These findings are important to understand and improve reprogramming of glial cells to neurons, and thus brings us closer to therapeutic solutions.”

About this neuroscience research news

Author: Constanze Drewlo
Source: LUM
Contact: Constanze Drewlo – LUM
Image: The image is credited to Neuroscience News

Original Research: Open access.
“Direct neuronal reprogramming of mouse astrocytes is associated with multiscale epigenome remodeling and requires Yy1” by Magdalena Götz et al. Nature Neuroscience